In a pooled analysis of clinical trial data on diabetic patients at high cardiovascular risk or with chronic kidney disease, canagliflozin demonstrated consistent benefits across the spectrum of age ...
A new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than ...
As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...